Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis

Journal of Bone and Joint Surgery

Volumn 91, Issue 6, 2009, Pages 1377-1386

  Dimar II, John R ^a   Glassman, Steven D ^a,b,c   Burkus, J Kenneth ^a,b,c   Pryor, Philip W ^a,b,c   Hardacker, James W ^a,b,c   Carreon, Leah Y ^a,b,c  

^a NORTON LEATHERMAN SPINE CENTER   (United States)

^b HUGHSTON CLINIC   (United States)

^c Spine Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; COLLAGEN; HYDROXYAPATITE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN;

ADULT; AGED; ARTHRITIS; ARTHRODESIS; ARTICLE; AUTOGRAFT; BACKACHE; BLEEDING; BONE GRAFT; BURSITIS; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DONOR SITE; DRUG FATALITY; DRUG INDUCED CANCER; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; ILIAC CREST; INFECTION; INJURY; INTERMETHOD COMPARISON; LEG PAIN; LENGTH OF STAY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEOPLASM; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; OPERATION DURATION; OSWESTRY DISABILITY INDEX; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; POSTEROLATERAL LUMBAR SPINE ARTHRODESIS; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PSEUDARTHROSIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SHORT FORM 36; SPINE DISEASE; SPINE FUSION; SPINE RADIOGRAPHY; SPONDYLOLISTHESIS; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; VERTEBRA FRACTURE; ADOLESCENT; AUTOTRANSPLANTATION; BONE TRANSPLANTATION; COMPARATIVE STUDY; CONFIDENCE INTERVAL; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; ILIAC BONE; LUMBAR VERTEBRA; METHODOLOGY; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDY; RADIOGRAPHY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPONDYLOSIS; TRANSPLANTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEINS; BONE TRANSPLANTATION; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; ILIUM; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPINAL FUSION; SPONDYLOSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649870799     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.H.00200     Document Type: Article

References (26)

1. Sandhu HS, Toth JM, Diwan AD, Seim HB 3rd, Kanim LE, Kabo JM, Turner AS. Histological evaluation of the efficacy of rhBMP-2 compared with autograft bone in sheep spinal anterior interbody fusion. Spine. 2002;27:567-575
2. Boden SD, Martin GJ Jr, Horton WC, Truss TL, Sandhu HS. Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage. J Spinal Disord. 1998;11:95-101.
3. Hecht BP, Fischgrund JS, Herkowitz HN, Penman L, Toth JM, Shirkhoda A. The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) to promote spinal fusion in a nonhuman primate anterior interbody fusion model. Spine. 1999;24:629-636 (Pubitemid 29162904)
4. Burkus JK, Heim SE, Gornet MF, Zdeblick TA. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech. 2003;16:113-122 (Pubitemid 36397568)
5. Burkus JK, Sandhu HS, Gornet MF, Longley MC. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am. 2005;87:1205-1212
6. Martin JG Jr, Boden SD, Marone MA, Marone MA, Moskovitz PA. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J Spinal Disord. 1999;12:179-186
7. Barnes B, Boden SD, Louis-Ugbo J, Tomak PR, Park JS, Park MS, Minamide A. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates. Spine. 2005;30:1127-1133 (Pubitemid 40695921)
8. Akamaru T, Suh D, Boden SD, Kim HS, Minamide A, Louis-Ugbo J. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine. 2003;28:429-434 (Pubitemid 36330828)
9. Suh DY, Boden SD, Louis-Ugbo J, Mayr M, Murakami H, Kim HS, Minamide A, Hutton WC. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. Spine. 2002;27:353-360 (Pubitemid 34224648)
10. Boden SD, Martin GJ Jr, Morone MA, Ugbo JL, Moskovitz PA. Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine. 1999;24:1179-1185 (Pubitemid 29279459)
11. Boden SD, Kang J, Harvinder S, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial. Spine. 2002;27:2662-2673 (Pubitemid 35425320)
12. Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy. 1980;66:271-273 (Pubitemid 11234479)
13. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;306:473-483
14. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32:40-66.
15. Pledger GW. Basic statistics: importance of adherence. J Clin Res Pharmacoepidemiol. 1992;6:77-81.
16. Glassman SD, Dimar JR, Carreon LY, Campbell MJ, Puno RM, Johnson JR. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion. Spine. 2005;30:1694-1698
17. Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine. 2002;27(16 Suppl 1):S26-31.
18. Ludwig SC, Kowalski JM, Boden SD. Osteoinductive bone graft substitutes. Eur Spine J. 2000;9 Suppl 1:S119-25.
19. Lind M, Bunger C. Factors stimulating bone formation. Eur Spine J. 2001;10 Suppl 2:S102-9.
20. Vaccaro AR, Sharan AD, Tuan RS, Kang JD, An HS, Morone MA, Savas PE, Hilibrand AS, Abitbol JJ. The use of biologic materials in spinal fusion. Orthopedics. 2001;24:191-199
21. Carreon LY, Glassman SD, Anekstein Y, Puno RM. Platelet gel (AGF) fails to increase fusion rates in instrumented posterolateral fusions. Spine. 2005;30:E243-7.
22. Urist MR. Bone: formation by autoinduction. Science. 1965;150:893-899
23. Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev. 1992;32:160-167
24. Ware JE Jr, Kosinski M, Keller SK. SF-36 physical and mental health survey scales: a user's manual. Boston: The Health Institute, New England Medical Center; 1994.
25. Fairbank JC, Pynsent PB. The Oswestry Disability Index. Spine. 2000;25:2940-2952
26. Walsh TL, Hanscom B, Lurie JD, Weinstein JN. Is a condition-specific instrument for patients with low back pain/leg symptoms really necessary? The responsiveness of the Oswestry Disability Index, MODEMS and the SF-36. Spine. 2003;28:607-615